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ABSTRACT
Small non-coding RNAs of 18–25nt in length can
regulate gene expression through the RNA
interference (RNAi) pathway. To characterize
small RNAs in HIV-1-infected cells, we performed
linker-ligated cloning followed by high-throughput
pyrosequencing. Here, we report the composition
of small RNAs in HIV-1 productively infected MT4
T-cells. We identified several HIV-1 small RNA
clones and a highly abundant small 18-nt RNA that
is antisense to the HIV-1 primer-binding site (PBS).
This 18-nt RNA apparently originated from the
dsRNA hybrid formed by the HIV-1 PBS and the 30
end of the human cellular tRNAlys3. It was found to
associate with the Ago2 protein, suggesting its
possible function in the cellular RNAi machinery
for targeting HIV-1.
INTRODUCTION
Small non-coding RNAs of 18–25nt in length are
important in the RNA interference (RNAi) mechanism
for controlling gene expression (1,2). An intermediate
step in the RNAi pathway is the processing of precursor
double-stranded (ds) RNAs into siRNA or miRNA by the
RNase III Dicer (3). Dicer recognizes and cleaves dsRNA
substrates into products of  18–25nt in length. Dicer
substrates can be long linear dsRNAs or hairpin RNAs
that have either perfectly complementary or imperfectly
complementary stems. The Dicer-cleaved siRNAs can
enter an Ago2-containing RNA-induced silencing complex
(RISC). This si–RISC complex can target and cleave a
mRNA that is recognized by base complementarity to the
guide siRNA. Alternatively, Dicer-produced miRNAs can
associate with RISC to form a mi–RISC complex which
can act to silence the translation of mRNA targets [review
(4) for further detail].
Dicer processes cellular miRNAs (5) and siRNAs (6).
However, several mammalian viruses, including HIV-1
(7–10), encode viral miRNAs which are also processed
by Dicer (11). To characterize small RNAs in HIV-1
infected cells (12,13), we performed small RNA cloning
followed by high throughput nucleotide pyrosequencing.
This approach identiﬁed many clones with discrete HIV-1
sequences and also a highly abundant clone containing a
cellular 18-nt non-coding RNA (PBSncRNA) sequence
which is antisense to the HIV-1 primer-binding sequence
(PBS). The latter ﬁnding of a PBSncRNA in HIV-1
infected cells is in agreement with two recent reports on
the identiﬁcation of similar PBS-complementary short
ncRNAs to endogenous retroviruses (14,15). HIV-1
PBSncRNA was found to be associated with an Ago2
protein intracellularly, suggesting that it is potentially
active in the cell’s RNAi pathway against HIV-1.
MATERIALS AND METHODS
Cell culture
HIV-1 latently infected human monocyte cell line, U1 and
human T-cell line, MT4, were cultured in RPMI 1640
medium with 10% fetal calf serum (FCS) and 2mM
L-glutamine. In U1 cells, HIV-1 virus production was
induced by treatment with 1mM phorbol myristate
acetate (PMA). HeLa and 293T cells were propagated at
37 C with 5% CO2 in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% FCS and
2mML-glutamine. To generate an AGO2-over expressing
cell line, 293T cells were transfected with either pFLAG-
AGO2 or an empty vector together with pRS (Origene).
Stable transformants (‘293T-AGO2’ for a line stably
expressing pFLAG-AGO2 and ‘293T-control’ for a
control cell line) were selected with 1mg/ml puromycin.
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DNA oligonucleotides corresponding to the PBS sequence
(50-CTAGTTGGCGCCCGAACAGGGACA-30;5 0-AGC
TTGTCCCTGTTCGGGCGCCAA-30) were hybridized
and cloned into the Spe I and Hind III sites of pMIR-
REPORT-Luc (Ambion). Control plasmid pMIR-
REPORT-b-gal (Ambion) encoding b-galactosidase was
used for luciferase assay normalization. PBS siRNA
(50-GUCCCUGUUCGGGCGCCAdTdT-30;5 0-UGGCG
CCCGAACAGGGACdTdT-30), PBS mut siRNA (50-A
CCCCUGGUCGGGCGCAAdTdT-30;5 0-UUGCGCCC
GACCAGGGGUdTdT-30), to knock down Dicer
protein si-Dicer (50-UGCUUGAAGCAGCUCUGG
AdTdT-30 and 50-UCCAGAGCUGCUUCAAGC
AdTdT-30) (16) and si-control (50-CUUUAAGCUCCCU
GAGCGUUU-30 with 50-ACGCUCAGGGAGCUUAA
AGUG-30) RNAs were synthesized by Invitrogen. The
expression plasmid for FLAG-AGO2 was prepared by
PCR using pIRESneo-FLAG/HA-AGO2 (17) as a
template.
Reporter assays
HeLa and 293T cells were co-transfected using
Lipofectamine 2000 (Invitrogen) with PBSncRNA or
PBSncRNA mutant and a pMIR-REPORT-Luc reporter
plasmid with (LucPBS) the addition of a single
PBSncRNA-complementary target site. The pMIR-
REPORT-b-gal plasmid was also added to the trans-
fection as a normalization control. Forty-eight hours
after transfection, cells were washed twice with 1 
phosphate-buﬀered saline and then lysed in 1  luciferase
lysis buﬀer (Promega). Luciferase assay substrate
(Promega) was used according to the manufacturer’s
protocol, and activity was measured in an Opticom II
luminometer (MGM Instruments). Normalization of
luciferase activity was based on b-galactosidase activity
measured with Galacto-Star as described by the manu-
facturer (Tropix, Bedford, MA, USA). All luciferase
values represent averages±SD from at least three
independent transfections.
Reverse transcriptase assay and viral infection
Media collected from pNL4-3 transfected HeLa cells, or
293T cells, or from PMA-treated U1 cells were ﬁltered
using 0.45-mm membrane. Virus was quantiﬁed by
Reverse transcriptase (RT) assay (18). In total, 10
6–10
7
cpm RT units of virus prepared from transfected HeLa
cells were used to infect 5 10
6 MT4 cells. After 2h of
exposure to virus, cells were washed twice with phosphate
buﬀered saline and resuspended into RPMI and cultured
for 48h. Supernatant RT was quantiﬁed, and the cells
were harvested for small RNA isolation using the
mirVana miRNA isolation kit (Ambion).
In vitro transcription
A T7 promoter driven 50-UTR region (from 584 to 710 nts
of pNL4-3) was PCR ampliﬁed by Taq polymerase
(Clontech) using DNA primers (T7 sense primer 50-TAA
TACGACTCACTATAGGGAGAGTAACTAGAGAT
CCCTCAGACCCTTTTAGTCAGTGTG-30 and reverse
primer 50-TTCAGCAAGCCGAGTCCTGCGTCGA-30).
The T7 promotor sequence is underlined. In vitro
transcription of the PCR product was carried out using
MAXIscript T7 Kit (Ambion) according to the
manufacturer’s protocol.
In vitro reverse transcription and in vitro Dicer assays
Ten nanograms of the in vitro synthesized RNA template
(T7PBS) was hybridized with total tRNA (BioS&T) using
conditions described in Beerens and Berkhout (19).
Reverse transcription of the mixture was carried out in
the presence of 20ng reverse primer (described earlier)
and SuperScript III (Invitrogen). Under the same
hybridization conditions, a mixture containing the total
tRNA and T7PBS was subjected to digestion with 1U
of recombinant Dicer (Genlantis) for 12h at 37 C.
The diced RNA was resolved in 15% acrylamide—8M
urea gel.
Preparation of AGO2-associated small RNA
293T-AGO2 or 293T-control cells were transfected with
pNL4-3 or pUC18 as a negative control. At 2days post-
transfection, cells were harvested with IP buﬀer [50mM
HEPES, 150mM NaCl, 10% glycerol, 1% NP-40,
1.5mM MgCl2, 0.2mM PMSF, 1mM DTT, protease
inhibitor (complete, Roche) and 100U/ml SUPERase-in
(Ambion)] followed by immunoprecipitation with anti-
FLAG agarose (Sigma), anti-AGO2 (Cell Signaling)
or mouse normal IgG (as control, Zymed laboratories)
with protein G/A agarose (Calbiochem). After six
washes, small RNAs in the immunoprecipitates
were recovered with mirVana miRNA isolation kit
(Ambion). To investigate the eﬀect of RT on
the production of PBSncRNA, 5mM of the non-nucleoside
reverse transcription inhibitor (nevirapine) was added 2h
before the cells were transfected, and the drug was
maintained throughout the entire transfection process.
Northern blot analysis
RNAs were separated using 15% polyacrylamide–8M
urea gel and electrotransferred for 1h at 200mA to
nylon membranes. After UV crosslinking, membranes
were prehybridized for 1h at 68 C in Ultrahyb
(Ambion) and incubated overnight at 37 C with cognate
probes. Membranes were washed extensively at room
temperature and autoradiographed.
Small RNA cloning
The cloning of small RNAs from HIV-1 infected MT4 cells
was conducted as described by Lau et al. (20). HIV-1 virus
(>1 MOI) derived from transfection of molecular clone
pNL4-3 into 293T cells was used to infect MT4 cells
for 2days. One-hundred micrograms of size-enriched
small RNAs (<200nt) were prepared from the infected
and uninfected cells and used for cloning followed by
sequencing. The classiﬁcation of small RNA sequences
was based on sequence analysis using the GenBank
database (http://www.ncbi.nlm.nih.gov/Genbank/), the
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sequences/), the rRNA database (http://bioinformatics
.psb.ugent.be/webtools/rRNA/blastrrna.html) and the
human tRNA database (http://lowelab.ucsc.edu/
GtRNAdb/), and the piRNA database (http://research
.imb.uq.edu.au/rnadb/FastaDownloads/382.aspx).
Quantitative real-time PCR
Small RNAs (<200nt) were isolated using mirVana
miRNA isolation kit (Ambion). miRNA quantiﬁcation
was as described earlier (21,22). RNA was polyadenylated
with ATP by poly(A) polymerase at 37 C for 1h using
RNA tailing kit (Ambion) and reverse transcribed using
0.5mg of poly(T) adapter primer (Invitrogen). For each
PCR, equal amounts of cDNA (ﬁrst normalized using
the snU6 RNA) were mixed with SYBR Green PCR
mix (ABI) and 5pmol of forward primer (designed on
the entire tested miRNA sequence) and reverse primer
(based on the adaptor sequence). Ampliﬁcation was
done under the condition of 15s at 95 C and 1min at
60 C for 55 cycles in an Opticon real-time PCR detection
system (Bio-Rad) or 7300 Real Time PCR System (ABI).
(Supplementary Figure S1). Random pNL4-3 primers
(HIVs3263 and HIVs5543) starting from 3263 nt (50-AT
GGACAGTACAGCCTATAGTGCT-30) and 5543 (50-A
ACTGACAGAGGACAGATGGAA-30) were used as
speciﬁcity controls.
To quantify luciferase mRNA and HIV-1 genomic
RNA, total RNA from transfected cells was harvested
by using the mirVana miRNA isolation kit (Ambion)
following the manufacturer’s protocol. Fifteen micro-
grams of total RNA were ﬁrst treated with RQ1 RNase-
free DNase (Promega) at 37 C for 30min followed by
phenol/chloroform extraction and ethanol precipitation.
One microgeam of the resuspended RNA was used for
RT reaction. The ﬁnal product was then phenol/
chloroform extracted and ethanol precipitated, and 1ng
of the product was used for quantiﬁcation. The qPCR
reaction was the same as described earlier. To detect
luciferase mRNA, forward primer 50-CTCGGGTGTAA
TCAGAAT-30 and backward primer 50-TTGCTAGTAC
CAACCCTA-30 were used. To detect HIV-1 genomic
RNA, forward primer 50-CTCTCTGGCTAACTAGGG
AAC-30 and backward primer 50-CAAGCCGAGTCCT
GCGTCGAGAGATC-30 were used. The results were
normalized to the amount of GAPDH mRNA measured
using forward primer 50-GCTCACTGGCATGGCCTTC
CGTGT-30 and backward primer 50-TGGAGGAGTGG
GTGTCGCTGTTGA-30.
RESULTS
Pyrosequencing of small RNAs in HIV-1 infected T-cells
Viral miRNAs have been reported for several viruses
(23,24). To understand better the small RNA proﬁle
of HIV-1 NL4-3 infected cells, we sequenced size-
fractionated small RNAs from virus infected MT4
T-cells. The MT4 cells were infected with HIV-1; and
2days later, small RNAs were harvested and cloned
(20). In total 47773 discrete clones were sequenced
(1004656nt) and analyzed. Consistent with other studies
(15,25) which identiﬁed miRNA as the largest ( 60%)
constituent of small RNAs, 52% of our small RNAs
were miRNAs (Figure 1A). In total, 24892 miRNA
clones corresponding to 398 discrete miRNA species
(Supplementary Table S1) were identiﬁed. The relative
distribution of our sequenced miRNA species is consistent
with the published literature on miRNAs expressed T-cells
(26). For instance, miRNAs including the miR-17-92
cluster (diﬀerent members in our library varied between
57 and 1276 clones), miR-21 (9521 clones) and miR-155
(409 clones) were highly represented in our sampling.
Nonetheless, 27% (107/398) of all the discrete miRNAs
identiﬁed in our study were cloned only once (Figure 1B).
In other studies, many bona ﬁde cellular miRNAs have
also been reported to be cloned as single copies (27–30).
For example, Berezikov et al. (30) reported that in their
library of 19291 mouse and 23351 human small RNA
clones, 28% of the known miRNAs were detected either
only once or not at all. In a separate respect, our miRNA-
cloning sensitivity may be slightly better than that
reported in some other studies (26) which identiﬁed and
cloned from Jurkat T-cell RNAs many fewer discrete
miRNA species [i.e. only 592 Jurkat miRNA clones were
sequenced by Landgraf et al. to reveal 60 individual
miRNAs (26)]. As noted elsewhere, the results from
various studies should be interpreted with caution since
diﬀerences could be due to dissimilar cell types,
methodologies, tissue culturing conditions and sample
size (31). Separately, of interest, 7.58% (3618 clones
representing 151 unique sequences) of our small RNAs
were piRNAs (Figure 1A). While piRNAs are generally
considered to be restricted in expression to germ line cells
(32,33), our identiﬁcation of piRNAs agrees with a report
of Ago2- and Ago3-associated piRNAs in Jurkat cells
(34). The role of piRNAs in somatic cells requires
further study.
Characterization of HIV-1 small ncRNAs
Amongst our 47773 clones, 125 HIV-1 entities with
sequence lengths of 15–26 were found (Supplementary
Table S2). Like cellular miRNAs, the largest class of
these viral clones encompassed those sequences (113)
that were cloned only once (six others were cloned twice
and one was cloned thrice). Because cloning proﬁciencies
may be operator-dependent, the functional implications
and quantitative interpretation of sequences that were
cloned singly versus doubly or triply are not clear,
especially since a plurality of authentic cellular miRNAs
was cloned only once by us (Supplementary Table S1). In
the singly cloned HIV-1 sequences, three observations are
noteworthy. First, we cloned a TARncRNA (Figure 2A,
left) that agrees with the reported isolation of up to 17
TAR miRNA clones by others (10). Second, we cloned a
NEFncRNA sequence (Figure 2A, middle) which is
complementary to a previously described NEF miRNA
(hiv1-miR-N367) [(9,35) discussed in more detail below].
Third, we cloned a ncRNA sequence (vsiRNA*)
(Figure 2B, left) which matches as the miRNA* strand
for a previously reported HIV-1 vsiRNA sequence (36).
Nucleic Acids Research, 2009,Vol.37, No. 19 6577These three cloned examples, although diﬃcult to
interpret by themselves, appear to independently conﬁrm
earlier published observations on small HIV-1 non-coding
RNAs. We also identiﬁed six HIV-1 RNA clones which
share an identical core sequence but diverged slightly in
their end nucleotides (Figure 2B, right, RREncRNA).
The RREncRNA maps proximal to the vsiRNA-
vsiRNA* sequence within the highly secondary structured
HIV-1 RRE stem I (Figure 2B). The variations in the
termini of RREncRNA clones may have arisen from
inexact Dicer end processing which has been noted by
others (14). The functional importance of TARncRNA,
NEFncRNA, vsiRNA/vsiRNA* and RREncRNA in
HIV-1 infected cells remains to be investigated.
It is technically challenging to clone low copy small
RNAs. Cloning, per se, may not be a quantitatively
reliable metric. In contrast, sequence speciﬁc real time
RT–PCR is a well-established measure of RNA copy
number. To assess better the abundance of HIV-1 small
RNAs, we next employed real-time quantitative RT–PCR
(RT–qPCR) to characterize TARncRNA, RREncRNA
and NEFncRNA (Figure 3). As expected, TARncRNA,
RREncRNA and NEFncRNA were detected in HIV-1
NL4-3 infected MT4, but not in uninfected control cells
(data not shown). As negative detection controls, we
randomly chose HIV-1 primer pairs that would measure
ncRNAs, if any, which corresponded to NL4-3 sequences
located at 3263 and 5543. These control primers produced
no detectable signals in virus infected MT4 cells (data not
shown). In contrast, sequence-speciﬁc RT–qPCR did
quantify 4 10
4 copies of TARncRNA, 187 copies of
RREncRNA and 607 copies of NEFncRNA, per 10
6
copies of cellular small U6 RNA. Based on published
data (37), there are  10
5 copies of U6 RNA per cell.
Hence, TARncRNA, RREncRNA and NEFncRNA,
normalized to U6, are calculated to be roughly 3 10
3,
19 and 61 copies per cell, respectively. We note that
several factors may inﬂuence the copy number detection
of small RNAs. For instance, it is possible that fewer than
100% of the MT4 cells were infected by HIV-1; this would
Figure 1. Pyrosequencing of small RNAs from HIV-1 infected T cells. (A) A pie chart indicates the distribution of diﬀerent cellular small RNAs.
(B) Distribution frequency showing the number of times that diﬀerent miRNAs were cloned.
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the stability of viral RNA structures and the likelihood
that RNAs with secondary structures are bound by
RNA-binding proteins (e.g. TAR- or RRE-binding
proteins) may aﬀect the accessibility of these sequences
to processing factors.
Small RNA processed from a PBS–tRNAlys3 duplex
Curiously, the most individually abundant HIV-1-related
clone (19 clones were isolated) from the infected MT4 cells
was an 18-nt ncRNA (PBSncRNA, Figure 4A) with a
perfectly matched antisense sequence to the viral PBS.
During HIV-1 replication, an RNA duplex is formed
between the PBS and cellular tRNAlys3 (Figure 4B)
with the 30-end of PBS-bound tRNAlys3 used as the
primer for reverse transcription. It is known that tRNA
maturation requires the addition of the CCA nucleotides
to the 30 terminus via the action of CCA-adding enzyme
(tRNA nucleotidyltransferase) (38). The detection of CCA
sequence in our PBSncRNA (Figure 4B) is consistent with
its origin from mature tRNAlys. Indeed, the cloning of
the 18-nt PBSncRNA as a discrete moiety suggests that
the PBS–tRNAlys3 hybrid might be processed by an
RNase III enzyme such as Dicer.
It is possible that the 18-nt PBSncRNA could be an
artifactual product of random tRNAlys3 degradation.
Two observations argue against this explanation. First,
the abundance of processed PBSncRNA was correlated
with HIV-1 expression. Thus increasing amounts of
PBSncRNA were detected when we transfected escalating
amounts of HIV-1 molecular clone pNL4-3 into 293T
cells (Figure 4C). This correlation with HIV-1 expression
was also illustrated by the ﬁnding that 19 copies of
PBSncRNA were cloned from HIV-1 infected MT4 cells
(Figure 4A) while in the corresponding uninfected MT4
cells only a single PBSncRNA clone was recovered
(data not shown). In northern blot analysis, detection
of PBSncRNA using a sequence-speciﬁc probe was
observed in HIV-1 pNL4-3 transfected (but not mock
transfected) HeLa cells and in PMA-induced (but
not mock induced) HIV-1 latently infected U1 cells
(Figure 4D, lanes 2 and 4).
Second, in the sequencing data from our infected MT4
cells, we quantiﬁed the copy number of PBSncRNA versus
other similar 18-nt ncRNAs that could have arisen
from nine other comparably abundant tRNA species
(Figure 4E). If the PBSncRNA were a product of
random degradation of tRNAly3, then one might expect
the other 30 tRNA 18-nt fragments from comparably
abundant tRNAs to be produced in closely equivalent
copy numbers. However, the tRNAlys3 PBSncRNA was
by far the most abundant moiety in HIV-1 infected MT4
cells, consistent with it arising from a viral PBS–tRNAlys3
dependent processing event (Figure 4E). Indeed, con-
sistent with this notion, two other groups have recently
described the unexpected cloning and pyrosequencing of
an abundant small ncRNA originating apparently from
the processing of an RNA hybrid formed from a tRNA
primer with the PBS from cell endogenous retroviruses
(14,15). For example, Kawaji et al. cloned and identiﬁed
in high abundance the discrete 30-end of tRNAGluCUC
RNA sequence 50-UCGUUUCCCGGUCAGGGAAC
CA-30 which is wholly complementary to the PBS (50-UG
GUUCCCUGACCGGGAAACGA-30) of Harlequin
(ERV1) (15). Similarly, Calabrese et al. (14) identiﬁed
an abundantly expressed short ncRNA sequence which is
anti-sense to the PBS of the transposon repeat, commonly
found in the early mouse embryo and ES cells (39–41).
Thus, these collective ﬁndings suggest that tRNA-viral
PBS hybrids could be ubiquitously processed into
discrete intracellular ncRNA species perhaps using either
RNAse III dependent or independent paths.
Next, we queried if a PBS–tRNAlys3 duplex could be
an in vitro substrate for Dicer. To address this question,
we performed Dicer assays using a T7 synthesized
32P-radiolabeled HIV-1 RNA that contains the PBS
sequence (T7PBS; Supplementary Figure S2). The
processing of the T7PBS RNA after annealing with a
primer pool of total cellular tRNAs with or without
added Dicer was monitored. A mostly unprocessed
T7PBS RNA (127bp) was observed when neither tRNA
nor Dicer was added (Figure 5A, lane 3). The addition of
Dicer-alone to the T7PBS RNA was insuﬃcient to
produce a processed 18-nt band (Figure 5A, lane 2).
However, the speciﬁc processing of the T7PBS RNA to
an 18-nt RNA occurred when both tRNA and Dicer were
added to the reaction (Figure 5A, lane 1, see * band).
These results suggest that Dicer can recognize and
process a T7PBS–tRNAlys3 hybrid into a ncRNA
product, although further investigation is needed to
elucidate how this processing might occur inside cells.
We also considered the possibility that the PBSncRNA
could be generated by the RNaseH cleavage activity
of the HIV-1 RT protein (42,43). We do not favor this
explanation for the following reasons. First, PBSncRNA
was produced in a single-cycle transfection of the HIV-1
NL4-3 molecular clone into cells (Figure 4C). This type of
assay does not involve a reverse transcription step.
Second, to check more directly that PBSncRNA is not a
result of RNaseH activity during a reverse transcription
step, we added nevirapine, a non-nucleoside reverse
transcriptase inhibitor, before and during the transfec-
tion of pNL4-3 into 293T-AGO2 cells (Figure 5B).
Figure 3. Quantiﬁcation of HIV-1 small RNAs by real-time RT–PCR.
The HIV-1 small RNAs (TARncRNA, RREncRNA and NEFncRNA)
were veriﬁed by quantitative RT–PCR using U6 small RNA for
normalization. Methodology in Supplementary Figure S1.
6580 Nucleic Acids Research, 2009,Vol.37, No. 19Figure 4. Detection of PBSncRNA that is antisense to the HIV-1 PBS. (A) Multiple copies of PBSncRNAs were cloned from HIV-1 infected MT4
cells. The numbering corresponds to pNL4-3 sequence. (B) A schematic diagram showing the duplex formed between the HIV-1 PBS with the 30-end
of tRNAlys3. PBSncRNA sequence is highlighted in grey. (C) Immunoprecipitation of the AGO2 protein followed by primer-speciﬁc RT–qPCR of
the AGO2-associated RNA shows that the amount of PBSncRNA quantiﬁed in 293T-AGO2 cells is dose-dependent on the amount of transfected
pNL4-3 (pNL). (D) Northern blot analysis demonstrating increased detection of PBSncRNA in PMA-induced HIV-1 latently infected U1 cells, and
in HIV-1 molecular clone (pNL4-3)-transfected HeLa cells (upper panel). Production of HIV-1 from the indicated cells was veriﬁed by measuring RT
activity (bottom panel). (E) Quantiﬁcation of the predicted processing of the 30-end of the indicated tRNAs in HIV-1 infected MT4 cells. The relative
detection of diﬀerent 30-end—tRNA fragments from the sequencing data is compared. The value of the 18-nt PBSncRNA from Lys(UUU)
(tRNAlys3) was set as 1. tRNA(UUU)=tRNAlys3.
Nucleic Acids Research, 2009,Vol.37, No. 19 6581The amount of PBSncRNA produced was essentially the
same in the presence or absence of nevirapine suggesting
that its production is RT-independent. Finally, we also
performed siRNA knock down of Dicer. By knocking
down Dicer, we indeed observed a reduction in the
amount of PBSncRNA compared to control cells
(Figure 5C).
Association of PBSncRNA with Ago2-RISC
What could be a possible fate for the PBSncRNA? Would
it functionally engage intracellular RISC? The Ago2
protein is a central component of RISC (44), and above
results in Figure 5C suggest that PBSncRNA can engage
RISC. To check in greater detail how PBSncRNA
can function with Ago2, a 293T cell line stably over-
expressing FLAG-tagged Ago2 (293T-AGO2) was
constructed. 293T-AGO2 cells were transfected with
pNL4-3, and Ago2 was immunoprecipitated using
anti-FLAG. The presence of PBSncRNA in the immuno-
precipitate was assessed by real-time RT–qPCR.
As a control, transfection of pNL4-3 into the parental
293T cell line was also immunoprecipitated in parallel
Figure 5. Evidence for the in vitro processing and intracellular RISC-incorporation of PBSncRNA. (A) In vitro Dicer assay of the HIV-1 PBS–tRNA
hybrid (the PBS containing radiolabeled transcript was made as described in Supplementary Figure S2) produced a small RNA of 18nt (asterisk;
lane 1). This small RNA was not observed in the absence of either tRNA (lane 2) or tRNA+Dicer (lane 3). As a positive control, in vitro T7 RNA
polymerase synthesized and then annealed ds GFP RNA (T7dsGFP) was processed in vitro by Dicer, which yielded the expected small RNAs of
 22bp (lane 4). (B) Non-nucleoside RT inhibitor (Nevirapine) does not aﬀect the expression of PBSncRNA in a single-cycle transfection of an HIV-
1 molecular clone. We transfected pNL4-3 into nevirapine treated (+; lanes 5–8) or untreated cells ( ; lanes 1–4) and subsequently quantiﬁed
PBSncRNA. Similar expression levels of PBSncRNA was detected in nevirapine treated (lane 7) and untreated (lane 3) 293T-AGO2 cells. Controls
include the immunopreciptation using anti-FLAG in control cell line (293T-cont) (lanes 1 and 5) and the attempted detection of a randomly selected
HIV-1 sequence (HIVs3263) (lanes 2, 4, 6 and 8). (C) siRNA knock down of Dicer reduced the expression of PBSncRNA. PBSncRNA was
quantiﬁed in 293T-AGO2 cells transfected with control-siRNA (si-cont) or Dicer-siRNA (si-Dicer) and co-transfected with pNL4-3. The amount
of AGO2-associated PBSncRNA was then quantiﬁed by RT–qPCR after immunoprecipitation with anti-AGO2 (lanes 1 and 2). Control immunopre-
cipitation was also performed with an irrelevant IgG (lanes 3 and 4). (D) Immunoprecipitation (IP) of FLAG-Ago2 using anti-FLAG or a control
IgG antibody was performed in a 293T-AGO2 cell line or in a control 293T parental cell line as described in the text. Quantitative real-time
RT–qPCR detection of the HIV-1 PBSncRNA or two randomly chosen HIV-1 sequences (HIVs3263 and HIVs5543) from the IP products was
performed. The value of the RT–qPCR result from the IP of 293T-AGO2 transfected with pNL4-3 was set as 1.
6582 Nucleic Acids Research, 2009,Vol.37, No. 19with either anti-FLAG or with an irrelevant IgG
control antibody (Figure 5D; lanes 1–8). A signiﬁcant
recovery of PBSncRNA from pNL4-3/293-AGO2 cells
was detected by RT–qPCR in the IP with anti-FLAG,
but not in the IP with IgG control antibody (Figure 5D;
compare lane 4–8); an insigniﬁcant amount of PBSncRNA
was seen in the immunoprecipitates from control and
mock transfected cells (Figure 5D; lanes 1–3 and lanes
5–7). To check further for speciﬁcity of detection,
we selected two random HIV-1 sequences (HIVs3263
and HIVs5543) for use in control RT–qPCR assays
(Figure 5D; lanes 9–24). In both instances, no speciﬁc
recovery was detected by these sequences in the
immunoprecipitations (Figure 5D; lanes 1, 3, 6 and 7).
Taken together, the results support the interpretation
of an intracellular association of PBSncRNA with
Ago2-RISC.
Over-expression of PBSncRNA modulated HIV-1
replication
If PBSncRNA-associates with Ago2, could this inter-
action result in an active RISC? We, next, constructed a
reporter plasmid containing a single PBS-target sequence
positioned downstream of a luciferase cDNA (LucPBS;
Figure 6A). Transfection of LucPBS with a synthetic
PBSncRNA at 5nM into HeLa cells produced a 40%
inhibition of luciferase activity (Figure 6B). Increasing
the amount of transfected PBSncRNA to 50nM increased
luciferase inhibition to 80% (Figure 6B). As control,
a parallel transfection of a mutant PBSncRNA
(PBSncRNA mutant) did not inhibit luciferase expression,
supporting that the observed PBSncRNA-silencing was
sequence speciﬁc.
To query the role of PBSncRNA-silencing in viral
biology, we examined how it might aﬀect single-cycle
of HIV-1 replication. HIV-1 molecular clone pNL4-3
was co-transfected into 293T cells with PBSncRNA or
PBSncRNA mutant, and virus production was measured
by checking for the release of RT into the culture
supernatant. Consistent with the results from the
luciferase reporter assays (Figure 6B), co-transfection of
the PBSncRNA, but not the PBSncRNA mutant,
produced a dose-dependent inhibition of virus RT
production (Figure 6C). Next, to ask whether the silencing
eﬀect of PBSncRNA is through destabilization of the
targeted RNA or through a mechanism of translational
inhibition, RT–qPCR was performed to quantify HIV-1
RNA with or without PBSncRNA transfection
(Supplementary Figure S3). The HIV-1 RNA copies
were signiﬁcantly decreased by transfected PBSncRNA
in a dosage-dependent manner (Supplementary Figure
S3). Finally, to ask if cell endogenous PBSncRNA
exhibits a similar anti-HIV-1 eﬀect as observed with
over expressed PBSncRNA, we reasoned that knocking
down the ambient level of PBSncRNA in cells could
make these cells more susceptible to HIV-1 replication.
We employed synthetic RNAs (antagomirs) designed
to knock down PBSncRNA. When these antagomirs
were introduced into cells, replication of HIV-1 in the
transfected cells was notably augmented (Figure 6D).
Collectively, the ﬁndings indicate that both over
expressed and physiologically expressed PBSncRNA
can serve modulating inﬂuences on HIV-1 replication
in cells.
Figure 6. Over expressed PBSncRNA or knock down of physiologically
expressed PBSncRNA can modulate viral replication. (A) A schematic
diagram of the LucPBS construct. A single copy of HIV-1 PBS
sequence (TGGCGCCCGAACAGGGAC) was positioned downstream
of the luciferase coding sequence. (B) Functional studies employing
synthetic dsRNA oligonucleotide corresponding to the PBSncRNA
or its mutated form, PBSncRNAmutant. Mutated nucleotides are
boxed. Diﬀerent concentrations (5 or 50nM) of the PBSncRNA and
PBSncRNAmutant were separately co-transfected with LucPBS
construct (described in A) into HeLa cells. The PBSncRNA inhibited
up to  80% the luciferase expression. (C) Similar experiments were
performed in 293T cells using HIV-1 molecular clone (pNL4-3) in a
single round replication assay (see text). The PBSncRNA eﬀectively
inhibited up to  80% of HIV-1 replication while no inhibition was
observed with PBSncRNAmutant. (D) De-repression of HIV-1
replication by knock down of cell endogenous PBSncRNA using RNA
‘antagomirs’. Co-transfection of pNL4-3 and increasing amount of
antagomirs, complementary to the PBSncRNA, in 293T cells increased
HIV-1 replication as measured by RT activities.
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Here, we have performed high throughput pyro-
sequencing of cloned RNAs from HIV-1 infected MT4
cells. We sequenced 47773 clones which included 128
viral small RNA entities. In examining the results,
several reasons suggest (although they do not fully
exclude) that most of our viral RNA sequences are
unlikely to be products of random degradation. First,
we employed a small RNA cloning technique which
requires the presence of intact 50 phosphate and 30 OH
ends (26). Degraded RNAs have non-phosphorylated
50-ends and are unlikely to be cloned by this technique.
Second, degradation products tend to have a wide-
distribution of lengths due to random cleavage. The
lengths of our cloned small RNA sequences are
narrowly restricted. Third, the presence of mRNA
sequences in a small RNA clone library can represent
an internal measure of degradation products. In our
library, only 2.41% of the small RNAs were mRNA-
derived (Figure 1A), a number consistent with other
studies, suggesting a limited contribution of degradation
to our cloning. Finally, in the case of PBSncRNA [which
has related examples described by others (14,15)], we
showed an association of this moiety with Ago2. This
type of association is compatible with a functionally
relevant interaction which is unlikely to occur for RNAs
generated by random degradation.
Several studies have reported on the cloning and
sequencing of small RNAs encoded by viruses (23,24).
Small viral RNAs have most prevalently been described
in Herpesvirus-infected cells (45). In HIV-1 research, a
recent study has performed small RNA-cloning and
pyrosequencing using the Ach2 ‘latent’ HIV-1-infected
cell line and found minimal representation of viral
sequences (26). However, the Ach2 ‘latent’ cell results
could be problematic because the HIV-1 provirus in
Ach2 cells contains a mutated TAR which renders the
LTR non-responsive to the viral transcriptional activator,
Tat. Indeed, it was shown previously that when the same
TAR-mutation in Ach2 cells was transferred into an
otherwise infectious molecular clone of HIV-1, the virus
became crippled for replication, and no viral production
was measured (46). Our study diﬀers from the Ach2-work
in employing the productive infection of MT4 cells with
a replication competent HIV-1 virus. As noted earlier,
our cloning of a wider-range of T-cell speciﬁc miRNAs
possibly indicate a greater sensitivity than that reported
by Landgraf et al. who sequenced 1098 Ach2-miRNA
clones (26) while we sequenced 24892 MT4-miRNA
clones. Nonetheless, one should be cautious about
interpreting diverse results since each infection system
and cloning method could have inherent constraints
which inﬂuence the precision of measurements (47).
Likely, with further improved sensitivity of cloning and
sequencing, small viral ncRNAs could be discovered for
an increasing number of mammalian viruses (48). Indeed,
in a recent small RNA cloning and pyrosequencing study
of four HTLV-1 infected/transformed cell lines, we have
also identiﬁed many discrete small viral ncRNAs (Yeung,
unpublished observations). It remains a future challenge
to determine the biological implications of small viral
ncRNAs in infected cells.
Although we do not yet understand the functions of
small HIV-1 ncRNAs, the identities of some clones are
consistent with the expectations from previous ﬁndings
(7–9). Bennasser et al. (49) and Omoto et al. (9) had
earlier predicted two potential miRNA-like hairpin
structures for TAR and NEF, respectively. Other
investigators have subsequently conﬁrmed the existence
and cloning of a TAR miRNA (7,8,10), and our cloning
(Figure 2A; Supplementary Table S2) and RT–qPCR
results (Figure 3) are concordant with these ﬁndings.
Omoto et al. (9,35) had also cloned one arm of a
Nef-miRNA (hiv1-mir-N367) hairpin (Figure 2A, right).
Interestingly, our NEFncRNA now appears to be the
hiv1-mir-N367* strand complementary to Omoto’s
Nef-miRNA (hiv1-mir-N367) sequence. Provocatively,
NEFncRNA can also assume an alternative hairpin
structure (Figure 2A, right, NEFncRNA-NEFncRNA*);
and the NEFncRNA* strand of this alternate hairpin
was also recovered in our cloning. In our viral RNA
sequences, we further identiﬁed a clone for a putative
complementary arm (vsiRNA1*) of a RNA-duplex that
contains the previously reported vsiRNA1 (36). The
vsiRNA1*-vsiRNA1 duplex maps to a highly secondary
structured RRE segment, which apparently also produces
a cloned RREncRNA (Figure 2B, right). Pending a better
comprehension of the roles played by these RNA
sequences, one interpretation is that these HIV-1 small
ncRNAs are products of processing by the cellular
RNAi machinery, and that their presence agrees with
evidence elsewhere that RNAi serves an innate antiviral
defense in mammalian cells (31,50).
Our pyrosequencing study also identiﬁed a small
18-nt antisense ncRNA (PBSncRNA) that is fully com-
plementary to the HIV-1 PBS (Figure 4). The abundance
of PBSncRNA is HIV-1 expression dependant, consistent
with a mechanism whereby much of this moiety is
processed from a PBS–tRNAlys3 duplex by Dicer
(Supplementary Figure S4). Although we were initially
surprised by this cloning, a closer inspection of the
literature revealed two recent studies which also described
the abundant cloning of discrete analogous PBSncRNAs
complementary to the PBS of endogenous retroelements
(14,15). Together, these three PBSncRNA ﬁndings ﬁt
a general notion that retroviral PBS–tRNA hybrid
duplex may be ubiquitously processed by the cell to yield
ncRNAs. The deliberate over expression of a HIV-1-PBS-
targeting ncRNA [Figure 6; and Han et al. (51)], like
other PBS-targeting molecules (52), can modulate viral
replication. We also observed that the knock down of
physiologically expressed PBSncRNA in cells increased
the replication of HIV-1 in these cells (Figure 6D)
suggesting that ambiently expressed PBSncRNA can
target intracellularly viral genomic sequence (53).
The suggestion that small HIV-1 ncRNAs and
PBSncRNA represent evidence that mammalian cells
employ RNAi to defend exogenous retroviral infection
agrees with the current view that RNAi is utilized by
cells to suppress mammalian endogenous retroviruses
(40,41,54–56). The ﬁndings also reconcile accumulating
6584 Nucleic Acids Research, 2009,Vol.37, No. 19evidence that mammalian viruses including HIV-1 encode
functional RNAi suppressors (which viruses should
encode if cells use RNAi-against viruses). Examples of
these suppressors include hepatitis C virus (HCV) core
and envelope protein 2 (57,58), vaccinia virus E3L (59),
Ebola virus VP35 (60), primate foamy virus Tas (61),
inﬂuenza A virus NS1 (59,62,63) and HIV-1 Tat
(36,50,64). Some of these suppressors may serve to
moderate Dicer activity (36,65), and/or sequester
dsRNA (59,62,63,66). Either mechanism could limit the
capacity by the cell to process viral sequences into small
ncRNAs, perhaps in part explaining some of the
challenges in detecting small viral ncRNAs in mammalian
cells. In the big picture, studying the strike-counter
strike interplay in nucleic acid-based RNAi restriction
between viruses and their hosts (67) may shed further
understanding on viral sequence evolution and viral
diversity.
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